Global COPD Market - Forecast to Reach $19 Billion by 2022 - Research and Markets

DUBLIN--()--The "Global COPD Market - by Type, Diagnosis, Treatment, Region - Market Size, Demand Forecasts, Industry Trends and Updates (2016-2022)" report has been added to Research and Markets' offering.

The global COPD market in 2016 was USD 13.7 billion and is estimated to reach USD 19 billion by 2022 at a CAGR of 5.6% during the forecasted period. Nucala and benralizumab will garner the North America sales, especially in the US.

COPD, or chronic obstructive pulmonary disease is a group of progressive lung diseases of which the common ones are emphysema and chronic bronchitis. According to a new Global Burden of Disease study, it is estimated that chronic obstructive pulmonary disease caused 3.2 million deaths globally in 2015. Disease burden due to COPD was highest in Papua New Guinea, India, Lesotho, and Nepal. People working in occupations like Agriculture, Mining, Plastics, etc among others are more prone to be affected by COPD.

Chronic obstructive pulmonary disease was the fifth cause of death in early years of 2000 and it is projected to be the fourth cause of mortality by 2025. Smoking is a major risk factor in men. In non-smoking women, unexpectedly, the prevalence of COPD is also high in high income countries, as well as in low and middle income countries. In low and middle income countries, COPD in women may be associated with biomass burning.

Companies Mentioned

  • Abbott
  • AstraZeneca
  • Dr. Reddy's Laboratories Ltd
  • F. Hoffmann-La Roche Ltd
  • Forest Labs
  • GSK
  • Galapagos NV
  • Merck
  • Mundipharma
  • Novartis AG
  • Nycomed
  • Orexo
  • Pfizer Inc
  • Roche

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Market Overview

4. Market Dynamics

5. Global COPD market Segmentation, Forecasts and Trends - by Revenue

6. By Type

7. By Diagnosis

8. By Treatment

9. By Region

10. Vendor Market Share Analysis

11. Company Profiles

12. Industry Structure

13. Global COPD market - Road Ahead

For more information about this report visit https://www.researchandmarkets.com/research/wcgczl/global_copd

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs